SHPH Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Shuttle Pharmaceuticals Holdings's net margin of -49.65%. Shuttle Pharmaceuticals Holdings's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Shuttle Pharmaceuticals Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.07%. Given that NovaBay Pharmaceuticals has higher upside potential than Shuttle Pharmaceuticals Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Shuttle Pharmaceuticals Holdings.

Shuttle Pharmaceuticals Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Shuttle Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Shuttle Pharmaceuticals Holdings quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Shuttle Pharmaceuticals Holdings's net income of -$1.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Shuttle Pharmaceuticals Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Shuttle Pharmaceuticals Holdings's net margin of -18.58%. Shuttle Pharmaceuticals Holdings's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Shuttle Pharmaceuticals Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Shuttle Pharmaceuticals Holdings has higher upside potential than Retractable Technologies, analysts believe Shuttle Pharmaceuticals Holdings is more attractive than Retractable Technologies.

Shuttle Pharmaceuticals Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Shuttle Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Shuttle Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Shuttle Pharmaceuticals Holdings's net income of -$1.6M is higher than Retractable Technologies's net income of -$1.9M. Notably, Shuttle Pharmaceuticals Holdings's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings is -- versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Shuttle Pharmaceuticals Holdings's net margin of -118.53%. Shuttle Pharmaceuticals Holdings's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Shuttle Pharmaceuticals Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 154.24%. Given that Stereotaxis has higher upside potential than Shuttle Pharmaceuticals Holdings, analysts believe Stereotaxis is more attractive than Shuttle Pharmaceuticals Holdings.

Shuttle Pharmaceuticals Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Shuttle Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Shuttle Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Shuttle Pharmaceuticals Holdings's net income of -$1.6M is higher than Stereotaxis's net income of -$7.5M. Notably, Shuttle Pharmaceuticals Holdings's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings is -- versus 5.60x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.